Clinical Trial Recruiting patient

Clinical Trial Recruiting patient

Recruiting Patients in Ongoing Studies Contact Detail: +91-9983656667, +91-9828683771 e-mail: whatsup No. 91-9828683771


Ongoing Studies



Study Title “A Prospective, Multicenter, Open-label, Phase IV, Interventional Study to Assess the Safety and Efficacy of Capmatinib in Indian Patients with Mesenchymal-Epithelial Transition (MET) exon 14 Skipping Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)” (Capmatinib)

Dr. Deepak Gupta



Study Title: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (TDXd) Versus Investigator’s Choice Chemotherapy in HER2 low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting ( DESTINY Breast06).

Dr. Deepak Gupta


Study Code: D9319C00001 Study Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1).

Dr. Deepak Gupta


Protocol Title: SPEAR(Study of PIK3CA mutations and Effectiveness and tolerability outcomes of Alpelisib in Real-world) A descriptive study of PIK3CA mutations and outcomes with Alpelisib in patients with HR-positive and HER2-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) in India. (PIK3CA mutations)

Dr. Deepak Gupta



Study Title: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR).

Dr. Deepak Gupta



Study Title: A Phase III, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8)

Dr. Aseem K Samar


Protocol#:21707 Protocol: A single-arm, open-label Phase 4 study of darolutamide in addition to standard androgen deprivation therapy for participants in Indian with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)

Dr. Aseem K Samar


Protocol Entitled: A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2(+) Metastatic Breast Cancer.

Dr. Tarachand Gupta


Protocol Title: A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma (MCL VEGA)

Dr. Upendra Sharma


A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of ImbruvicaTM (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion (Ibrutinib)

Dr. Upendra Sharma


A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone- sensitive prostate cancer (mHSPC)

Dr. Pawan Agarwal